Literature DB >> 7700663

Rhinorrhea is decreased in dogs after nasal application of botulinum toxin.

C M Shaari1, I Sanders, B L Wu, H F Biller.   

Abstract

At this time no effective long-term therapy exists for the excessive secretion of vasomotor rhinitis. Because rhinorrhea is under parasympathetic control, it was theorized that botulinum toxin--a powerful and long-acting cholinergic blocker that has been successful in the treatment of dystonia--might be useful in blocking the cholinergic control of rhinorrhea. Four male mongrel dogs were studied. Fifty units of type A botulinum toxin was soaked into sterile gauze, which was then packed into the left nasal cavity of each dog for 1 hour. Saline-soaked gauze was similarly introduced into the right nasal cavity to serve as control. Six days later, rhinorrhea was produced by inserting a bipolar needle electrode into the sphenopalatine ganglion and electrically stimulating for 10 minutes (6 mA, 50 Hz). Nasal secretions were collected with a suction catheter placed in the nasal vestibule. Three of four dogs exposed to the toxin showed a 41% average decrease in rhinorrhea (specifically 53%, 41%, and 30%). One dog showed a 10% increase in secretion after exposure to the toxin. We conclude that topically applied botulinum toxin reduced neurally evoked rhinorrhea by an average of 41%. Because some secretion is mediated by noncholinergic neurotransmitters such as vasoactive intestinal peptide, topical application of an anticholinergic substance has limitations. However, because all the nasal parasympathetic nerves appear to originate from cholinergic synapses in the sphenopalatine ganglion, direct injections of toxin into this ganglion may possibly allow complete blockade of all cholinergically mediated rhinorrhea.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7700663     DOI: 10.1177/019459989511200410

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  10 in total

Review 1.  [Botulinum toxin in otorhinolaryngology - an update].

Authors:  R Laskawi; A Olthoff
Journal:  HNO       Date:  2017-10       Impact factor: 1.284

2.  The use of botulinum toxin as primary or adjunctive treatment for post acne and traumatic scarring.

Authors:  Greg J Goodman
Journal:  J Cutan Aesthet Surg       Date:  2010-05

Review 3.  Botulinum Toxin for Rhinitis.

Authors:  Cengiz Ozcan; Onur Ismi
Journal:  Curr Allergy Asthma Rep       Date:  2016-08       Impact factor: 4.806

4.  Histopathological and radiological investigations of the influence of botulinum toxin on the submandibular gland of the rat.

Authors:  Berna Uslu Coskun; Hayati Savk; Esin Derin Cicek; Tulay Basak; Muzaffer Basak; Burhan Dadas
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-07       Impact factor: 2.503

Review 5.  [Botulinum toxin in otorhinolaryngology].

Authors:  S Rohrbach; R Laskawi
Journal:  HNO       Date:  2004-07       Impact factor: 1.284

6.  An Algorithm Using Botox Injections for Facial Scar Improvement in Fitzpatrick Type IV-VI Skin.

Authors:  Debraj Shome; Stuti Khare; Rinky Kapoor
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-08-08

7.  Comparison between botulinum toxin and steroid septal injection in the treatment of allergic rhinitis.

Authors:  Cheng-Chieh Huang; Kuan-Wei Chen; Chih-Wen Twu; Hung-Meng Huang; Hsin-Chien Hsu
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-01-06

8.  Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis.

Authors:  Saskia Rohrbach; Katharina Junghans; Sibylle Köhler; Rainer Laskawi
Journal:  Head Face Med       Date:  2009-10-16       Impact factor: 2.151

9.  Intraprostatic botulinum toxin injection in patients with benign prostatic enlargement.

Authors:  Cristian P Ilie; Michael B Chancellor; Yao-Chi Chuang; Mischianu Dan
Journal:  J Med Life       Date:  2009 Oct-Dec

10.  The Effect of Gelfoam Impregnated With Botulinum Toxin on Allergic Rhinitis.

Authors:  Vahid Zand; Mohammadhossein Baradaranfar; Mohammadhossein Dadgarnia; Mojtaba Meybodian; Sedighe Vaziribozorg; Mohammad Mandegari; Nasrin Behniafard; Amrollah Dehghani
Journal:  Iran J Otorhinolaryngol       Date:  2019-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.